Table 3. Prevalence of Metabolic Abnormalitiesa in PCOS Women with and without IRS.
| Component | Total (n=318) | PCOS with IRS (n=86) | PCOS without IRS (n=232) | P valueb |
|---|---|---|---|---|
| TG ≥1.7 mmol/L | 65 (20.4) | 51 (59.3) | 14 (6.0) | <0.01 |
| HDL-C <1.29 mmol/L | 137 (43.1) | 75 (87.2) | 62 (26.7) | <0.01 |
| BP ≥130/85 mm Hg | 18 (5.7) | 11 (12.8) | 7 (3.0) | <0.01 |
| IFGc/IGTd | 75 (23.6) | 51 (59.3) | 24 (10.3) | <0.01 |
| Presence of metabolic abnormalities | ||||
| 0 | 124 (39.0) | NA | 124 (53.4) | |
| 1 | 108 (34.0) | NA | 108 (46.6) | |
| 2 | 66 (20.8) | 66 (76.7) | NA | |
| 3 | 20 (6.3) | 20 (23.3) | NA | |
| 4 | 0 | 0 | NA |
Values are expressed as number (%).
PCOS, polycystic ovary syndrome; IRS, insulin resistance syndrome; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; BP, blood pressure; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NA, not applicable.
aBased on the American College of Endocrinology (ACE) 2003 criteria [14]. Levels modified from the updated Adult Treatment Panel III 2005 guidelines [17]; bComparison was performed between PCOS women with and without IRS using the chi-square test with asymptotic significance (2-sided) for continuity correction; cFasting glucose 5.6 to 6.9 mmol/L. The original ACE 2003 definition identified impaired fasting glucose as 6.1 to 6.9 mmol/L (110 to 125 mg/dL) [14]. This was modified in 2004 by the American Diabetes Association (ADA) from 6.1 to 5.6 mmol/L. This new the cut-off for defining IFG is consistent with the latest ADA 2017 guidelines [66, 67]; d2-Hour oral glucose tolerance test 7.8 to 11.0 mmol/L.